ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

HQY

95.14

-1.2%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

HQY

95.14

-1.2%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

HQY

95.14

-1.2%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

HQY

95.14

-1.2%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

HQY

95.14

-1.2%↓

Search

Johnson and Johnson

Закрыт

СекторЗдравоохранение

186.77 -1.86

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

186.58

Макс.

190.27

Ключевые показатели

By Trading Economics

Доход

-5.5B

5.5B

Продажи

250M

24B

P/E

Средняя по отрасли

18.663

37.461

Прибыль на акцию

2.8

Дивидендная доходность

2.63

Рентабельность продаж

23.321

Сотрудники

138,100

EBITDA

-1.2B

7.5B

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+8.5% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

2.63%

2.33%

Дата следующей выплаты дивидендов

9 дек. 2025 г.

Следующая эксдивидендная дата

25 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

6.8B

467B

Предыдущая цена открытия

188.63

Предыдущая цена закрытия

186.77

Новостные настроения

By Acuity

36%

64%

111 / 373 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Johnson and Johnson График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

14 окт. 2025 г., 10:35 UTC

Отчет

J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains

14 окт. 2025 г., 10:51 UTC

Обсуждения рынка
Отчет

J&J Sales Get Boost From Tremfya Drug -- Market Talk

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson Raises 2025 View To Sales $93.5B-$93.9B Vs Prior View $93.2B-$93.6B >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson Now Sees 2025 Operational Sales of $93B-$93.4B Vs Prior Range $92.7B-$93.1B >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson Now Sees 2025 Adjusted Operational Sales Growth of 3.5%-4% Vs Prior Outlook 3.2%-3.7% >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson Backs 2025 Adj EPS $10.80-Adj EPS $10.90 >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q Worldwide MedTech Sales $8.43B >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson: 3Q MedTech Business Delivered Operational Sales Grew 5.6%, Driven Primarily by Electrophysiology Products, Abiomed, Shockwave, Wound Closure Pdts and Surgical Vision >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson: 3Q Innovative Medicine Operational Sales Grew 5.3%, With Net Acquisitions and Divestitures Positively Affecting Growth by 1.6% Due to Caplyta >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q International Sales $10.29B >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson Still Sees 2025 Adjusted Operational EPS $10.63-$10.73 >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson: Increasing 2025 Operational Sales Growth to Be in Range of 4.8%-5.3% Vs Prior Range 4.5%-5% >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson: 3Q Innovative Medicine Operational Sales Growth Driven by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya, Simponi/Simponi Aria and Spravato >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q Adj EPS $2.80 >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q Orthopaedics Sales $2.27B >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q Worldwide Innovative Medicine Sales $15.56B >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q U.S. Sales $13.71B >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q Sales $23.99B >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q EPS $2.12 >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q Orthopaedics Sales $2.27B >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q EPS $2.12 >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q Worldwide MedTech Sales $8.43B >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q U.S. Sales $13.71B >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q International Sales $10.29B >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q Worldwide Innovative Medicine Sales $15.56B >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q Net $5.15B >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q Adj EPS $2.80 >JNJ

14 окт. 2025 г., 10:20 UTC

Отчет

Johnson & Johnson 3Q Sales $23.99B >JNJ

14 окт. 2025 г., 10:03 UTC

Популярные акции

Stocks to Watch Tuesday: JPMorgan, Goldman Sachs, Ford -- WSJ

10 окт. 2025 г., 16:19 UTC

Приобретения, слияния, поглощения

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Johnson and Johnson Прогноз

Целевая цена

By TipRanks

8.5% рост

Прогноз на 12 месяцев

Средняя 206.47 USD  8.5%

Максимум 225 USD

Минимум 176 USD

Основано на мнении 19 аналитиков Wall Street, спрогнозировавших целевые цены для Johnson and Johnson  на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

19 ratings

12

Покупка

7

Удержание

0

Продажа

Техническая оценка

By Trading Central

154.93 / 155.895Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

111 / 373Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
help-icon Live chat